

CANCER

4

A COMPREHENSIVE TREATISE

BIOLOGY OF TUMORS: Surfaces, Immunology, and
Comparative Pathology

CANCER 4

A COMPREHENSIVE TREATISE

BIOLOGY OF TUMORS: Surfaces, Immunology, and Comparative Pathology

FREDERICK F. BECKER, EDITOR

New York University School of Medicine

(内部交流)

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Becker, Frederick F

Biology of tumors.

(*His Cancer, a comprehensive treatise; v. 4*)

Includes bibliographies and index.

1. Cancer cells. 2. Cancer—Immunological aspects. 3. Oncology, Experimental. 4. Tumors, Plant. I. Title. [DNLM: 1. Neoplasms. QZ200 C2143]

RC261.B42 vol. 4 [RC262] 616.9'94'008s 75-28176

ISBN 0-306-35204-4 (v. 4) [616.9'94'07]

© 1975 Plenum Press, New York

A Division of Plenum Publishing Corporation

227 West 17th Street, New York, N.Y. 10011

United Kingdom edition published by Plenum Press, London

A Division of Plenum Publishing Company, Ltd.

Davis House (4th Floor), 8 Scrubs Lane, Harlesden, London, NW10 6SE, England

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Reprints of individual contributions may be obtained from the author or from the publisher. Address reprint requests to Dr. J. H. T. Gammie, Department of Pathology, Division of Cancer Cause and Prevention, National Institutes of Health, Bethesda, Maryland 20205. Address reprint requests to Dr. Ettore Appella, Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20205. Address reprint requests to Dr. Michael R. Price, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England.

Contributors

to Volume 4

A. C. ALLISON, Clinical Research Centre, Harrow, Middlesex, England

TADAO AOKI, Viral Oncology Area, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

ETTORE APPELLA, Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland

ROBERT W. BALDWIN, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England

ARMIN C., BRAUN, The Rockefeller University, New York, New York

ISAIAH J. FIDLER, University of Pennsylvania, Philadelphia, Pennsylvania

SIDNEY H. GOLUB, Division of Oncology, Department of Surgery, and Department of Microbiology and Immunology, University of California School of Medicine, Los Angeles, California

LLOYD W. LAW, Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland. Present address: Frederich Cancer Research, Frederich, Maryland

GARTH L. NICOLSON, Department of Cancer Biology, The Salk Institute for Biological Studies, San Diego, California, and Department of Developmental and Cell Biology, University of California, Irvine, California

JAN PONTÉN, The Wallenberg Laboratory, University of Uppsala, Uppsala, Sweden

MICHAEL R. PRICE, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England

JAMES C. ROBBINS, Department of Cancer Biology, The Salk Institute for Biological Studies, San Diego, California

DANTE G. SCARPELLI, The University of Kansas Medical Center, College of Health Sciences and Hospital, Kansas City, Kansas

LOUIS R. SIBAL, Viral Oncology Area, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

- HAROLD L. STEWART, Registry of Experimental Cancers, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- MARY J. TEVETHIA, Department of Pathology and Cancer Research Center, Tufts University School of Medicine, Boston, Massachusetts
- SATVIR S. TEVETHIA, Department of Pathology and Cancer Research Center, Tufts University School of Medicine, Boston, Massachusetts

relationship between carcinogenesis and cancer, and the biology of the malignant cell. The second part, "Risks and Strategies," includes a chapter on global patterns of carcinogenesis and cancer, and a chapter on how to conduct studies of normal cells, but also emphasizes that the major problem in cancer research is to identify the malignant cell and to determine its unique characteristics. This book is the third volume in the series, "Cancer and Carcinogenesis," which has been published by Academic Press.

John D. Burchenal

Preface

As was shown in the first two volumes of this series, great strides have been made in identifying many of the agents or classes of substances responsible for carcinogenesis and in delineating their interactions with the cell. Clearly, the aim of such studies is that, once identified, these agents can be eliminated from the environment. Yet, despite these advances and the elimination of some important carcinogenic agents, one major problem exists. It is a constant monitor of all oncologic study and diminishes the importance of every experiment and of every clinical observation. *As we noted earlier, that problem is our inability to define the malignant cell.* It is through studies of the fundamental biology of tumors that we seek this definition.

A vast amount of information has been gathered which describes *what* this cell does and—to a lesser extent—*how* it does it. But the *why* evades us. We have been unable to define the malignant cell, save in broad terms by comparing it to its normal counterpart. The major problem appears to be that the malignant cell does so much. It is a chimera, mystifyingly composed of normal activities and structures, of phenotypic schizophrenia with embryonic, fetal, and adult characteristics and, occasionally, a hint of an unclassifiable capacity unique to malignant cells.

The clues as to the *why* of cancer function must be derived directly or by induction from the *what* and *how*. Malignant cells replicate when replication is not required. Whether by escaping the normal inhibitory controls of the host, or by supersensitivity to stimulation, or by some defect other than these, the tumor grows. The growth is noncompensatory and nonfunctional. The malignant cell also lives beyond its normal span. Together, growth and increased life span result in disruptive cellular accumulation. And what is more, malignant cells compete rather than participate with their normal neighbors and then competitively invade and destroy. The malignant cell itself evades destruction by humoral, immunological, and cellular defense mechanisms. It is therefore characterized by autonomous behavior, living off the host rather than with it. Are these abnormal activities the result of a single alteration or many? One integrated pattern or many? And what genetic or epigenetic or genetic-epigenetic alteration is responsible for this successful, this deadly capacity? An examination of the biology of

tumors presented in Volumes 3 and 4 serves many purposes. It may enable us to better understand normal cell biology. It may suggest crucial cellular alterations induced by carcinogenic agents. And, by understanding its aberrations of control and the advantages thus gained by the malignant cell, we may be better able to find a means of reversing them and halting their destructive processes.

New York

Frederick F. Becker

Contents

Spread of Tumors

Surfaces of Normal and Transformed Cells 1

JAMES C. ROBBINS AND GARTH L. NICOLSON

1. Introduction	3
2. Organization of Cell Surfaces	5
2.1. Basic Principles of Membrane Structure	5
2.2. Fluid Nature of Membranes	9
3. Differences Between Normal and Transformed Cell Surfaces	12
3.1. Composition	12
3.2. Enzymes	23
3.3. Transport	29
3.4. Other Surface Properties	31
4. Conclusion	40
5. References	40

Contact Inhibition 2

JAN PONTÉN

1. Introduction	55
2. The Normal Nonneoplastic Cell at Rest	58
2.1. Glia Cells and Fibroblasts	58
2.2. Epithelium	64
2.3. Wandering Cells	64
2.4. Summary of the Resting Normal Cell	65
3. Normal Cells in Motion	65
3.1. Locomotion of Fibroblasts and Glia	65

x	CONTENTS		
	3.2. Locomotion of Epithelial Cells	70	
	3.3. Locomotion of Wandering Cells	70	
	3.4. Comparison Between Movements of Different Normal Cell Types	73	
	3.5. Summary of Normal Cell Locomotion	74	
	4. Locomotion of Isolated Neoplastic Cells	75	
	4.1. Locomotion of Spontaneously Transformed (Tumorigenic) Cells or Cells Derived from Tumors <i>in Vivo</i>	76	
	4.2. Locomotion of Virally Transformed Cells	78	
	5. Social Behavior of Normal Cells in Culture	79	
	5.1. Definition and Assay of Contact Inhibition	80	
	5.2. Contact Inhibition Among Normal Cells	81	
	5.3. Mechanism of Normal Contact Inhibition	85	
	6. Social Behavior Among Malignant Cells	87	
	6.1. Carcinoma Cells	87	
	6.2. Glioma Cells	87	
	6.3. Sarcoma Cells	87	
	6.4. Social Behaviour of Lymphoma and Leukemia Cells	90	
	6.5. Significance of Contact Inhibition for Tumor Dissemination <i>in Vivo</i>	90	
	7. Conclusion	93	
	8. References	94	

Mechanisms of Cancer Invasion and Metastasis 3

ISAIAH J. FIDLER

1. Introduction	101
2. Invasion	102
2.1. Cellular Multiplication and Mechanical Expansion	102
2.2. Characteristics of Tumor Cell Growth <i>in Vitro</i>	103
2.3. Adhesiveness and Motility of Tumor Cells	104
2.4. Destruction or Modification of Host Tissues	105
2.5. Effects of Host Factors on Tumor Invasion	106
3. Metastasis	107
3.1. Metastasis by Direct Extension	107
3.2. Lymphatic Metastasis	107
3.3. Hematogenous Metastasis	112
4. Speculations on Tumor-Host Interaction	122
4.1. Unique Characteristics of Metastatic Tumor Cells	122
4.2. Host Immune Response and Metastasis	123
5. Conclusion	126
6. References	127

1. Introduction	135
2. Biochemical Properties of H-2 Antigens	136
3. Biological Properties of H-2 Antigens	138
4. Tumor Antigens	139
4.1. Tissue Specificity Antigens	140
4.2. Species Antigens	140
4.3. Receptor Site Antigens	140
4.4. Fetal and Embryonic Antigens	141
4.5. Tissue- or Organ-Type Specific Antigens	141
4.6. Other Antigens Provided by <i>H</i> Loci	141
4.7. Virion and Cellular Antigens of MuLVs	141
5. Tumor-Specific Antigens of Transplantation Type	142
6. Characterization of TSTA	143
7. Isolation, Solubilization, and Purification of Tumor-Associated Membrane Antigens	143
8. Isolation, Solubilization, and Partial Purification of Tumor Antigens with Tumor Rejection Activity	149
8.1. Characteristics of Soluble TSTA on SV40-Induced Neoplasms	150
8.2. Characteristics of Soluble RBL-5 TSTA	151
8.3. Distinction Between New Cellular Antigen (TSTA) and Viral Antigens on RBL-5 Leukemic Cells	152
9. Conclusion	154
10. References	154

RNA Oncogenic Virus-Associated Antigens (and Host Immune Response to Them) 5

TADAO AOKI AND LOUIS R. SIBAL

1. Introduction	159
2. Virion Antigens	160
2.1. Viral Envelope Antigens	160
2.2. Intraviral Antigens	163
3. Virus-Induced Antigens	166
3.1. Cell Surface Antigens	166

xii	CONTENTS	3.2. Intracellular Antigens	171
		3.3. Soluble Antigens	172
	4. Host Immune Response	173	
	4.1. Protection	173	
	4.2. Escapes	174	
	5. Comments	175	
	5.1. Detection of Virus Expression	175	
	5.2. Host Immune Response	176	
	6. References	178	

DNA Virus (SV40) Induced Antigens 6

SATVIR S. TEVETHIA AND MARY J. TEVETHIA

1. Introduction	185
2. Tumor Induction and Cell Transformation by SV40	186
3. Antigens in Tumor or Transformed Cells	189
3.1. Intracellular Antigens	190
3.2. Surface Antigens Associated with SV40-Transformed Cells	192
4. Antigens Induced in Productive Cycle	193
5. Genetic Origin of SV40 Induced Antigens	193
6. Immune Response	197
6.1. Immune Response in Permissive Host	197
6.2. Immune Response in Nonpermissive Host	197
7. Role of Antigens in Neoplasia	200
8. Conclusion	202
9. References	203

Immunobiology of Chemically Induced Tumors 7

MICHAEL R. PRICE AND ROBERT W. BALDWIN

1. Introduction	209
2. Nature of Immune Reactions Elicited Against Tumor Antigens	210
2.1. Cell-Mediated Responses	210
2.2. Humoral Antibody	214
3. Immunological Reactions Correlated with Tumor Status	215
3.1. Cell-Mediated Immunity	215
3.2. Humoral Antibody	219
3.3. Nature of Serum Factors Modifying Cell-Mediated Immunity	220
4. Conclusion	229
5. References	230

Immunological Surveillance Against Tumor Cells

A. C. ALLISON

1. Introduction	237
2. Polyoma Virus in Mice	239
3. Leukemogenic Viruses in Mice	243
4. Murine Sarcoma Virus	244
5. Effects of Immunosuppression on Other Tumors in Experimental Animals	245
6. Immunosuppression in Human Transplant Recipients	246
7. Malignancy in Other Immunosuppressed Patients	247
8. Malignant Disease in Children with Immunodeficiency	248
9. Rejection of Homotransplants of Cancer Cells	250
10. Immunological Stimulation and Malignancy	250
11. Infectious Mononucleosis and Burkitt's Lymphoma	251
12. Viruses of the SV40-Polyoma Group	253
13. Evidence For and Against Surveillance	254
14. References	255

Host Immune Response to Human Tumor Antigens

9

SIDNEY H. GOLUB

1. Introduction	259
2. Methodology of Human Tumor Immunology	260
2.1. Methods for the Assessment of Cell-Mediated Immunity	261
2.2. Human Tumor Serology	272
3. The Nature of the Host Response	276
3.1. Humoral Immunity	276
3.2. Cellular Response	278
3.3. Cell Interactions with Serum Factors	284
4. Conclusions and Speculations	288
5. References	291

Comparative Pathology

Comparative Aspects of Certain Cancers

10

HAROLD L. STEWART

1. Introduction	303
2. Historical Material	304

3. Registries and Publications	306
4. Criteria for Diagnosis of Cancer.....	308
5. Hyperplasia and Benign and Malignant	309
6. Tumors of the Lung	312
6.1. Rodents	313
6.2. Domestic Animals	316
6.3. Cattle	317
6.4. Zoo Animals	318
7. Tumors of the Liver	320
7.1. Mouse	320
7.2. Rat	330
7.3. Other Animals	338
8. Tumors of the Mammary Gland	340
8.1. Rat	340
8.2. Mouse	345
8.3. Domestic Animals	348
8.4. Other Animals	356
9. Tumors of the Soft Tissues	356
10. Hemangiosarcoma (Malignant Hemangioendothelioma).....	362
11. References	367

Neoplasia in Poikilotherms

11

DANTE G. SCARPELLI

1. Introduction	375
2. The Distribution and Characteristics of Some Common Neoplasms in Poikilotherms	376
2.1. Reptiles	376
2.2. Amphibians.....	377
2.3. Fishes	378
2.4. Primitive Vertebrates and Invertebrates	383
3. Neoplasm or Reaction to Injury?	384
3.1. General Considerations	384
3.2. Selected Examples	385
4. Etiological and Biological Perspectives	390
4.1. Chemical Carcinogens.....	391
4.2. Viruses	394
4.3. Immunity and Neoplasia	396
4.4. Regeneration and Neoplastic Growth in Urodeles	400
4.5. Imaginal Disc Differentiation and Neoplasia in Insects	401
4.6. Abnormal Growth in Hydra	403
5. References	404

ARMIN C. BRAUN

1. Introduction	411
2. The Development of Autonomy	413
2.1. The Regulation of Cell Growth and Division	413
2.2. Specific Substances Involved in the Regulation of Growth	414
2.3. Evidence That Specific Substances Are Involved in the Development of Autonomy	415
2.4. Evidence That the Persistent Activation of Normally Repressed Biosynthetic Systems Results in Autonomy	415
2.5. Evidence for an Extensive Activation of Biosynthetic Systems as a Result of the Neoplastic Transformation	416
2.6. Changes in the Properties of the Membrane Systems That Influence Autonomy	417
2.7. The Nature and Mode of Action of the Cell-Division-Promoting Factors	417
3. The Heritable Cellular Change That Underlies the Tumorous State in Plants	420
3.1. The Usefulness of Plant Tumor Systems for Studying the Heritable Cellular Change	420
3.2. Habituation	421
3.3. The Kostoff Genetic Tumors	422
3.4. The Crown Gall Disease	423
3.5. Specific Substances and Mechanisms Involved in the Reprogram- ming of Genetic Information with a Resulting Loss of Neo- plastic Properties	424
4. References	425
Index	429

Spread of Tumors

It is now well known that the spread of tumors is due to the migration of tumor cells from the primary tumor to other parts of the body. This process is called metastasis. Metastasis can occur through the lymphatic system or the bloodstream. In the lymphatic system, tumor cells travel through lymph nodes and lymph vessels. In the bloodstream, tumor cells travel through the blood vessels. Once tumor cells have traveled to another part of the body, they can form new tumors there. These new tumors are called secondary tumors or metastatic tumors. The ability of tumor cells to spread is determined by various factors, such as the type of tumor, the location of the tumor, and the characteristics of the tumor cells. Some tumors are more likely to spread than others. For example, breast cancer is a type of tumor that is known to spread easily. Other types of tumors, such as skin cancer, are less likely to spread. The spread of tumors can be prevented or treated with various therapies, such as surgery, chemotherapy, and radiation therapy.

Surfaces of Normal and Transformed Cells

JAMES C. ROBBINS and GARTH L. NICOLSON

1. Introduction

Considerable data implicate events at the cell surface as having a primary role in the growth, development, and communication of normal animal cells and in the multiplication of cancer cells. For example, surface changes are of particular relevance in determining whether neoplastic cells provoke a host immune response and whether they survive or succumb to that response. Surface characteristics are also at least partially involved in the ability of cancer cells both to establish a primary growth site and to metastasize to secondary sites. A variety of additional factors are involved in each case, but progress in distinguishing neoplastic from normal cell surfaces will surely help to understand and to combat the development and growth of neoplastic cells.

Little detailed biochemical knowledge of animal cell surface structure and behavior has been available until recently. In the last few years, several new techniques and approaches—for example, freeze-fracture electron microscopy, lectin biochemistry, covalent labeling of cell surface molecules, and electron spin resonance spectroscopy—have produced vast quantities of data on normal and neoplastic cell surfaces. The data are still somewhat fragmentary, and in some areas contradictory, but a coherent picture of the cell surface is gradually emerging.

Actual tumors arise from unknown precursor cells, so most basic studies have relied on model systems such as tumor virus transformation of “normal” cells.

JAMES C. ROBBINS and GARTH L. NICOLSON • Department of Cancer Biology, The Salk Institute for Biological Studies, San Diego, California, and Department of Developmental and Cell Biology, University of California, Irvine, California.